logo
60 Degrees Pharmaceuticals to submit tafenoquine MUMS designation request to FDA

60 Degrees Pharmaceuticals to submit tafenoquine MUMS designation request to FDA

60 Degrees Pharmaceuticals (SXTP) announced that the company will conduct a gap analysis of its existing data prior to submitting a minor use minor species designation request to the FDA for tafenoquine for the treatment of acute canine babesiosis. The submission will be based on results of three clinical efficacy studies that evaluated Arakoda for canine babesiosis, and existing canine safety data and chemistry manufacturing and controls data for tafenoquine generated through the clinical development of Arakoda for malaria.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025

Business Wire

time9 minutes ago

  • Business Wire

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release second quarter 2025 financial and operational results before markets open on July 31, 2025. Aurinia's management team will host a conference call and webcast on July 31, 2025, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-9170 / +1 201-493-6756. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA‑approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.

Ord Minnett Sticks to Its Buy Rating for Pantoro Gold Limited (RKN)
Ord Minnett Sticks to Its Buy Rating for Pantoro Gold Limited (RKN)

Business Insider

time2 hours ago

  • Business Insider

Ord Minnett Sticks to Its Buy Rating for Pantoro Gold Limited (RKN)

Ord Minnett analyst Paul Kaner maintained a Buy rating on Pantoro Gold Limited today and set a price target of A$4.00. The company's shares closed last Friday at €1.64. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Kaner covers the Basic Materials sector, focusing on stocks such as Aurelia Metals , AIC Mines Limited, and Pantoro Gold Limited. According to TipRanks, Kaner has an average return of 22.9% and a 63.28% success rate on recommended stocks. Currently, the analyst consensus on Pantoro Gold Limited is a Moderate Buy with an average price target of €2.03, which is a 23.78% upside from current levels. In a report released on July 3, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $0.00 price target. Based on Pantoro Gold Limited's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €153.43 million and a net profit of €6.62 million. In comparison, last year the company earned a revenue of €93.76 million and had a GAAP net loss of €15.8 million

YouTube (GOOGL) Has Taken Over TV, and UK Regulators Are Not Happy About It
YouTube (GOOGL) Has Taken Over TV, and UK Regulators Are Not Happy About It

Business Insider

time2 hours ago

  • Business Insider

YouTube (GOOGL) Has Taken Over TV, and UK Regulators Are Not Happy About It

Tech giant Alphabet's (GOOGL) YouTube has become one of the most powerful entertainment platforms, especially on TV screens. It started out as a website for short, low-budget videos, such as how-to guides or skateboarding clips. However, it's now the most-watched video platform on televisions in the U.S., according to The Wall Street Journal. As a result, many YouTube creators are producing longer, higher-quality videos for families and groups to watch together. YouTube is also improving its TV app to encourage people to watch longer by adding features like auto-playing the next episode and personalized suggestions. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. These longer videos are more valuable because they can include more ads, which equates to more revenue for both creators and Alphabet. YouTube is also investing in live sports, such as NFL games, and adding tools like 'multi-view' so fans can watch several games at once. As a result, YouTube has become a full replacement for traditional TV for many people. But not everyone is happy about this shift. In fact, UK media regulator Ofcom is worried that public service broadcasters (PSBs), like the BBC and Channel 4, could disappear as more people watch YouTube and Netflix (NFLX), according to the Financial Times. Therefore, Ofcom says that these public channels need more online visibility, and it wants the government to consider laws that would require YouTube to promote PSB content, especially for kids and news. While smart TVs already make sure that PSBs appear on home screens, their online reach is shrinking and accounts for only 9% of views. With most viewers no longer watching regular broadcast TV, Ofcom believes stronger rules and more cooperation are needed to protect UK-made public content. Is Google Stock a Good Buy? Turning to Wall Street, analysts have a Strong Buy consensus rating on GOOGL stock based on 29 Buys and nine Holds assigned in the past three months. Furthermore, the average GOOGL price target of $206.18 per share implies 9% upside potential from current levels.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store